Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$20.10 USD
-0.11 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.11 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FMS 20.10 -0.11(-0.54%)
Will FMS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FMS
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
Other News for FMS
GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
Doctors perform first combined heart pump and pig kidney transplant surgery
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
FMS Crosses Above Key Moving Average Level